Myriem Tamimy gives an overview of the ongoing situation for Janssen and pharma multinationals more generally in Morocco, discusses the next steps in the authorities’ pharma strategy and the role that multinationals will have in the process, and highlights the challenges related to managing in a time of COVID-19.
It is time for [Morocco] to upgrade and create a new type of jobs in the clinical research area, which is aligned to the Ministry of Industry’s expansion plan
Sofia Lahlou, country manager for women’s and children’s health specialist Versalya in the Moroccan market, discusses the company’s formation, its therapeutic priorities, and the opportunities that exist for women in…
Fadela Benjelloun, executive director of LEMM, the association of multinational pharma companies in Morocco, explains the association’s key goals of improving access to healthcare and medicines, positioning Morocco as an…
Dr Driss Chaoui, CEO of Afric-Phar, one of the leading domestic companies in Moroccan pharma, provides insight into the major developments that have taken place at the company since we…
PharmaBoardroom’s ten most-read executive interviews of 2021 reflect the wide scope – in terms of both geography and value chain – that our work has taken on in the past…
Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
See our Cookie Privacy Policy Here